Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multi-stakeholder mixed methods study
CONCLUSION: These data indicate that 'as needed' biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost effectiveness is warranted, to enable the real-world potential of this approach to be realised.PMID:38366988 | DOI:10.1093/bjd/ljae068 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: David Gleeson Maneeha Naveed Lucy Moorhead Helen McAteer Georgia Sewell Arlene McGuire John Weinman Jonathan N W N Barker Sam Norton Sarah C E Chapman Catherine H Smith Satveer K Mahil Source Type: research
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial
CONCLUSIONS: Although benralizumab resulted in near-complete depletion of blood eosinophils, there was no clinical benefit over placebo.PMID:38367194 | DOI:10.1093/bjd/ljae067 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: Sabine Altrichter Ana Maria Gim énez-Arnau Jonathan A Bernstein Martin Metz Lila Bahadori Maria Bergquist Laura Brooks Calvin N Ho Priya Jain Pradeep B Lukka Eva Rodriguez-Su árez Claire Walton Catherine J Datto ARROYO Study Investigators Source Type: research
A guide to improving the design and analysis of observational studies on the long-term safety of topical corticosteroids
Br J Dermatol. 2024 Feb 16:ljae065. doi: 10.1093/bjd/ljae065. Online ahead of print.NO ABSTRACTPMID:38366624 | DOI:10.1093/bjd/ljae065 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: Aaron M Drucker Peter C Austin Jane Harvey Stephanie J Lax Mina Tadrous Kim S Thomas Source Type: research
Intravenous gentamicin therapy induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients: An open label clinical trial
CONCLUSIONS: IV gentamicin induced readthrough of nonsense mutations in RDEB patients and restored functional C7 in their skin, enhanced wound healing, and improved clinical parameters. IV gentamicin may be a safe, efficacious, low cost, and readily available therapy in this population of RDEB patients.TRIAL REGISTRATION: Clinicaltrials.gov Identifiers: NCT03392909.PMID:38366625 | DOI:10.1093/bjd/ljae063 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: David T Woodley Michelle Hao Andrew Kwong Brandon Levian Jon Cogan Yingping Hou Daniel Mosallaei Elana Kleinman Kate Zheng Claire Chung Gene Kim David Peng Mei Chen Source Type: research
Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study
CONCLUSIONS: The highest rate of cirAEs and subsequent survival benefits were observed in cutaneous malignancies treated with ICIs. This study improves our understanding of patients who are at highest risk of developing cirAEs and would, therefore, benefit from appropriate counseling and closer monitoring by their oncologists and dermatologists throughout their ICI therapy. Limitations include its retrospective nature and cohort from one geography.PMID:38366637 | DOI:10.1093/bjd/ljae053 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: Guihong Wan Sara Khattab Bonnie W Leung Shijia Zhang Nga Nguyen Matthew Tran Chuck Lin Crystal Chang Nora Alexander Ruple Jairath Jordan Phillipps Kimberly Tang Ahmad Rajeh Leyre Zubiri Steven T Chen Shadmehr Demehri Kun-Hsing Yu Alexander Gusev Shawn G K Source Type: research
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
CONCLUSION: Xeligekimab showed high efficacy and is well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.PMID:38366639 | DOI:10.1093/bjd/ljae062 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Authors: Lin Cai Congjun Jiang Guoqiang Zhang Hong Fang Jinyan Wang Yumei Li Hui Xu Rong Xiao Yangfeng Ding Kun Huang Chunlei Zhang Litao Zhang Bin Chen Xinsuo Duan Weili Pan Guangming Han Rongyi Chen Lunfei Liu Shoumin Zhang Juan Tao Xiaowen Pang Jianbin Yu Huipi Source Type: research
Editor's Choice - John Ingram - March 2024
Br J Dermatol. 2024 Feb 16;190(3):i-ii. doi: 10.1093/bjd/ljae015.NO ABSTRACTPMID:38366826 | DOI:10.1093/bjd/ljae015 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
Outcomes that need to be assessed in pyoderma gangrenosum clinical trials
Br J Dermatol. 2024 Feb 16;190(3):e34. doi: 10.1093/bjd/ljae029.NO ABSTRACTPMID:38366827 | DOI:10.1093/bjd/ljae029 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
Results from the Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS)
Br J Dermatol. 2024 Feb 16;190(3):e33. doi: 10.1093/bjd/ljae028.NO ABSTRACTPMID:38366828 | DOI:10.1093/bjd/ljae028 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
Greater understanding about the role of a long non-coding RNA in the development of cutaneous squamous cell carcinoma
Br J Dermatol. 2024 Feb 16;190(3):e36. doi: 10.1093/bjd/ljae031.NO ABSTRACTPMID:38366829 | DOI:10.1093/bjd/ljae031 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
A review of the role of the NLRP1 inflammasome in skin conditions
Br J Dermatol. 2024 Feb 16;190(3):e27. doi: 10.1093/bjd/ljae022.NO ABSTRACTPMID:38366830 | DOI:10.1093/bjd/ljae022 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis
Br J Dermatol. 2024 Feb 16;190(3):e29. doi: 10.1093/bjd/ljae024.NO ABSTRACTPMID:38366831 | DOI:10.1093/bjd/ljae024 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index
Br J Dermatol. 2024 Feb 16;190(3):e28. doi: 10.1093/bjd/ljae023.NO ABSTRACTPMID:38366832 | DOI:10.1093/bjd/ljae023 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
Comorbidities in people with psoriasis
Br J Dermatol. 2024 Feb 16;190(3):e31. doi: 10.1093/bjd/ljae026.NO ABSTRACTPMID:38366833 | DOI:10.1093/bjd/ljae026 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
Safety of combination therapy for psoriasis: findings from the BIOBADADERM registry
Br J Dermatol. 2024 Feb 16;190(3):e30. doi: 10.1093/bjd/ljae025.NO ABSTRACTPMID:38366834 | DOI:10.1093/bjd/ljae025 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 17, 2024 Category: Dermatology Source Type: research
